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Poster Session-II 153Pediatric hematopoietic stem cell transplantation (HSCT) is
a lengthy, dynamic and complex medical procedure requiring multi-
ple invasive procedures. Although the procedure is accepted to treat
and ameliorate a variety of medical conditions, the process has dele-
terious physiological and psychological consequences. One of the
more common medical problems experienced by HSCT patients is
pain. Causes of pain in this patient population are multi-factorial,
but frequently can be attributable to conditioning regimen-related
toxicities (e.g., mucositis), medical procedures (e.g., catheter inser-
tions), and medication administration (e.g., subcutaneous injections).
As a result, the pain experienced by HSCT recipients significantly
and adversely impacts their medical course, performance status and
quality of life as well as the quality of life of those around them. Ef-
forts to lessen the duration and decrease the intensity of pain experi-
enced by children undergoingHSCT are crucial to successful patient
outcomes and improved quality of life. We have implemented one
method to address an aspect of this medical need through the use
of an indwelling catheter (insuflone; manufactured by Unomedical,
Denmark) as a means of administering subcutaneous medications.
Prior to the initiation of therapies administered subcutaneously, an
insuflon catheter is placed by the nurse. Training for catheter place-
ment is straightforward and can be accomplished within 30 minutes
using a preceptor model. The catheter is allowed to remain in place
for up to seven days and avoids daily insertion of a needle into the sub-
cutaneous tissue to deliver prescribed medications. We will summa-
rize our experience with using insuflon catheters in HSCT patients
for the administration of Neupogen (filgrastim) and Lovenox
(enoxaparin). Educational materials for health care professionals as
well as for patients and their caregivers will be presented. Addition-
ally, as a result of our success with insuflon catheters in our HSCT
recipients, policies and procedures for expanding the use of this cath-
eter to other patient populations as well as for the administration of
additional agents will be shared. This information is expected to be
of widespread interest since by decreasing the pain and anxiety sur-
rounding daily subcutaneous injections we have positively impacted
the quality of life of patients and care givers as well as strengthened
the healthcare professional-patient relationship.PHARMACY435
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Palifermin is recommended by the American Cancer Society to re-
duce the incidence and severity of mucositis in patients undergoing
high-dose chemotherapy with total body irradiation (TBI) prior to
autologous stemcell transplant (SCT). Since approval, results of stud-
ies of palifermin have been mixed. This study was undertaken to de-
termine the impact of palifermin on the incidence and severity of
mucositis in a high-risk population of SCT recipients who received
a variety of conditioning regimens at a large teaching institution.
We retrospectively compared outcomes of 18 palifermin-treated
SCT recipients with those of 33 patients managed prior to palifermin
availability. Paliferminwasdosed 60micrograms/kg/day IV for 3 days
prior to chemotherapy and 3 days after stem cell infusion. Controls
were matched based on type of malignancy, preparative regimen,
and high-risk features (dialysis, CrCl \60 mL/min, Karnofsky
performance score\70, allogeneic stem cell source). All patients re-
ceived peripheral stem cells, and 16.7% of palifermin patients and
18.2% of controls received those from an allogeneic source. Multiple
myeloma was the most common diagnosis, and melphalan was the
most common conditioning agent (both 76.4%).Only 11%of palifer-
min patients and 12.1%of controls received TBI.Median duration of
mucositis was 17 (3–42) days for palifermin patients vs. 12 (4–41) days
for controls (p 5 0.06). A total of 66.7% of palifermin patients vs.
51.5% of controls experienced grade 3–4 mucositis (p 5 0.38), for
a median duration of 9 (4–33) vs. 7 (3–18) days, respectively (p 5
0.05). Palifermin-treated patients did not experience a shortermedian
length of stay, and there was no significant difference in duration of
opioid or parenteral nutrition use. Based on these findings, palifermindoes not appear to provide significant benefit in the SCT population
at this institution to justify its cost. Further research is warranted to
determine under which conditions palifermin provides positive
outcomes.436
EVALUATING CLINICAL PHARMACY SERVICES IN A LEUKEMIA/BMT MED-
ICAL INTERVENTION CLINIC: A PILOT PROJECT
Warkentin, D.I.1, Lacaria, K.1, Partovi, N.1, Berryman, K.1, Smith, C.2
1Vancouver Coastal Health, Vancouver, BC, Canada; 2BC Cancer
Agency, Vancouver, BC, Canada
Introduction: There has been a significant increase in the number
of patients requiring either chemotherapy or HSCT being treated as
outpatients at the Leukemia/BMT Program of B.C. These patients
are complex medically and are on a greater number of medications.
Clinical pharmacy services are provided to the inpatient Leukemia/
BMT unit but not the outpatient clinic. Various studies have demon-
strated that the provision of clinical pharmacy services can significantly
reduce the occurrence of adverse drug events and improve patient
outcomes. Also the availability of clinical pharmacists can reduce the
occurrence of medication errors and significantly reduce drug costs,
thought the promotion of rational and cost effective medication use.
Main Thesis: The Leukemia/BMT Outpatient clinic received
full time clinical pharmacist for a six-month trial. During this evalu-
ation period and as part of quality improvement efforts by pharmacy
administration, services have been documented manually and by
using a personal digital assistant (PDA). Data fields as described by
Hepler and Strand, currently used in the inpatient unit, were used
and all other interventions were documented manually1. Interven-
tions were categorized into the following: patient access, patient
safety, cost containment, improved quality of patient care, reduced
workload and improved staff morale. SUMMARY This is the first
Canadian study to document considerable contributions of a clinical
pharmacy in an outpatient leukemia/HSCT clinic providing direct
patient care. These findings indicate clinical pharmacy services are
essential in providing quality patient care in an outpatient setting.
Conclusion: Permanent funding for a clinical pharmacist in the
Outpatient Leukemia/BMT Program is justified.437
SUBCUTANEOUS ADMINISTRATION OF ALEMTUZUMAB (CAMPATH-1H)
IS WELL TOLERATED AND EFFECTIVE
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Alemtuzumab (campath-1H) is a humanized anti-CD52monoclo-
nal antibody that has been successfully used as part of conditioning
regimes for HSCT to prevent GVHD. Intravenous alemtuzumab
is associated with frequent infusion related toxicity. We hypothe-
sized that subcutaneous alemtuzumab would be better tolerated
and effective. We have treated 32 patients receiving HSCT for
mainly non-malignant diseases with a reduced-intensity preparatory
regime including campath-1H, fludarabine, and melphalan. Sixteen
patients were given intravenous alemtuzumab, 14 subcutaneous
alemtuzumab and 2 a combination of 2 doses subcutaneous alemtu-
zumab followed by 2 doses of intravenous alemtuzumab. Fifteen pa-
tients had immune deficiency diseases, 6 metabolic disorders, 6
HLH, 3 Schwachman Diamond syndrome, 1 Kostmann’s syndrome
and 1 MDS. Age range was 4 months to 15 years. All patients re-
ceived bone marrow except one cord blood. Twenty seven donors
were unrelated, 4 matched siblings, and 1 unrelated donor umbilical
cord. Patients who received subcutaneous or intravenous alemtuzu-
mab showed similar drops in lymphocyte counts at Day15 and Day
17 after alemtuzumab. Thirteen of 16 patients receiving intravenous
alemtuzumab had fever associated with administration, 10 had rash
and 11 reported other toxicities as rigors, chills, hives, pruritus,
tachycardia, hypotension, nausea, vomiting, and headache. In the
group receiving subcutaneous alemtuzumab, 7 of 16 developed fe-
vers, 2 developed rash and 3 reported other toxicities as nausea,
chills, and tachycardia. The incidence of GVHD was similar in the
two groups, 5 of 16 in the intravenous group and 8 of 16 in the sub-
cutaneous group. Survival was similar in the two groups, with 16 of
18 surviving at day 100 in the intravenous group and 15 of 16 in the
